Jacobson Pharma publishes FY2026 annual report

• Jacobson Pharma released its 2025/2026 annual report, citing stable operations as demand for cold and flu medicines normalized.
• Growth focus shifted toward chronic disease and specialty medicines, supported by new launches and a larger in-licensed portfolio.
• Pipeline expanded to 241 products; 23 new products secured regulatory clearance during the year.
• Advanced therapeutics logistics scaled up for CAR-T therapy Yikaida in Hong Kong and Macau, with initial patient treatments completed.
• Tai Po InnoPark smart manufacturing project advanced with a main contractor appointed; first trial production targeted in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobson Pharma Corporation Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12247269), on July 16, 2026, and is solely responsible for the information contained therein.